Cetagliptin
Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM) . Cetagliptin is a substrate for P-glycoprotein. Cetagliptin reduces the GLP-1 degradation, maintains the level of postprandial blood sugar, and can be used in type 2 diabetes mellitus research[1].
Product Specifications
CAS Number
2243737-33-7
UNSPSC
12352101
Target
Cytochrome P450; Dipeptidyl Peptidase; P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
O=P(O)(O)O.FC(F)(C1=NC=C2N1CCN(C(C[C@H](N)CC3=C(C=C(C(F)=C3)F)F)=O)[C@@H]2C)F
Molecular Formula
C18H21F6N4O5P
Molecular Weight
518.35
References & Citations
[1]Zhou C, et al., Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) . 2024 Mar 11;15:1359407. |[2]Lu J, et al., In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. Xenobiotica. 2021 Oct;51 (10) :1122-1131.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
